Glenmark Life Sciences Ltd (GLS) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Glenmark Life Sciences Ltd stock ₹463, price ₹1,449, that is 68.1% below the price, quality 66 out of 100. Rating: strongly overvalued. Calculated from audited financials with 25 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Glenmark Life Sciences Ltd
GLS · BSEFar too expensive (fair value 68% below the price), but solid company and rising price: meets 2 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.
How to read this chart
60‑month range ₹343.59 – ₹1,521 · fair‑value band ₹304.67 – ₹662.50 · the ₹1,449 price screens above the ₹462.52 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 15, 2026.
Every Wednesday you see whether Glenmark Life Sciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Alivus Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India.
Show moreShow less
The company offers various APIs, such as olmesartan, telmisartan, perindopril, atovaquone, solifenacin, mirabegron, sitagliptin, zonisamide, adapalene, and rosuvastatin. It also provides contract development and manufacturing services to a range of multinational corporations and specialty companies.
The company's APIs are used in various therapeutic segments, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, and anti-infectives.
It also exports its products to Europe, North America, Latin America, Japan, and internationally. The company was formerly known as Glenmark Life Sciences Limited and changed its name to Alivus Life Sciences Limited in December 2024. The company was incorporated in 2011 and is based in Mumbai, India.
Alivus Life Sciences Limited is a subsidiary of Nirma Limited.
Stock analysis
Glenmark Life Sciences Ltd (GLS) currently trades at ₹1,449, while our model-based Fair Value estimate is ₹462.52, 68% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ₹820.97 per share, and 0 of the 25 models we run sit above the ₹1,449 price.
Bear case: the Asset-Based group reads lowest at ₹114.08, and 25 of the 25 models stay below the price. Data coverage for this calculation is high.
Scenario range: ₹304.67 (bear) to ₹662.50 (bull), the price of ₹1,449 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 66/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Glenmark Life Sciences Ltd reported revenue of ₹21.8B in FY2024 versus ₹15.4B in FY2020, a compound +9.2%/yr. Reported net income was ₹4.7B in FY2024, compounding +10.7%/yr from FY2020.
Key figures
Market cap ₹177B (≈ $1.9B) Small · P/E ratio 40.3 · P/S ratio 8.11 · EPS (TTM) ₹35.92 · Dividend yield 2.1% · Net margin 19.2% · Return on equity 17.2% · Return on assets (EBIT) 24.3% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 72 out of 100 (medium confidence).
What moves the price
The share trades about 5% below its 52-week high and 68% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −68%, GLS screens richer than that median.
Fair Value models
All 25 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Growth Forecast
GLS screens overvalued: fair value 68% below the price. Compare with Merck KGaA →
Compare Glenmark Life Sciences Ltd with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- EBIT margin by industry
- P/S ratio by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: Indian Stocks
- Valuation of the India market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Zoetis Inc ZTS | $83.82 | $113.53 | +35% | vs GLS |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥48.07 | ¥53.04 | +10% | vs GLS |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,880 | ₹1,983 | +5% | vs GLS |
| Haleon plc HLN | $9.17 | $8.47 | −8% | vs GLS |
| Merck KGaA MRK | €149.60 | €108.83 | −27% | vs GLS |
| Galderma Group GALD | CHF 191.40 | CHF 112.30 | −41% | vs GLS |
| Takeda Pharmaceutical Company TAK | $21.43 | $11.20 | −48% | vs GLS |
| Sandoz Group SDZ | CHF 84.60 | CHF 40.54 | −52% | vs GLS |
| Teva Pharmaceutical Industries Limited TEVA | $44.50 | $20.74 | −53% | vs GLS |
| Divi's Laboratories Limited DIVISLAB | ₹11,442 | ₹1,567 | −86% | vs GLS |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Glenmark Life Sciences Ltd (GLS) overvalued or undervalued?
What is the fair value of GLS?
What is the quality score of GLS?
What is the price target for Glenmark Life Sciences Ltd (GLS)?
What is the Glenmark Life Sciences Ltd stock forecast for 2026?
What is the revenue of Glenmark Life Sciences Ltd (GLS)?
Does Glenmark Life Sciences Ltd pay a dividend?
How much is the dividend of Glenmark Life Sciences Ltd (GLS)?
What growth is priced into Glenmark Life Sciences Ltd (GLS)?
What discount rate (WACC) does the fair value of GLS use?
What is a reverse DCF?
How much growth has Glenmark Life Sciences Ltd (GLS) delivered so far?
How fast is the sector of Glenmark Life Sciences Ltd (GLS) growing?
What is the free cash flow yield of Glenmark Life Sciences Ltd (GLS)?
What is the intrinsic value of Glenmark Life Sciences Ltd (GLS)?
Is Glenmark Life Sciences Ltd stock overvalued or undervalued in 2026?
Is fair value the same as the market price of GLS?
How much is Glenmark Life Sciences Ltd worth?
What do the bullish and bearish scenarios say about GLS?
What is the P/E ratio of GLS?
How solid is the balance sheet of Glenmark Life Sciences Ltd (GLS)?
How far is GLS from its 52-week high?
Which stocks are comparable to Glenmark Life Sciences Ltd?
Is Glenmark Life Sciences Ltd stock attractive at the current price?
How is the fair value of GLS calculated?
Is it still worth investing in stocks now?
What is the share price of Glenmark Life Sciences Ltd (GLS)?
What should I pay attention to with Glenmark Life Sciences Ltd right now?
Key figures of Glenmark Life Sciences Ltd
How large is the market capitalisation of Glenmark Life Sciences Ltd (GLS)?
What is the P/S ratio of Glenmark Life Sciences Ltd (GLS)?
What are the earnings per share of Glenmark Life Sciences Ltd (GLS)?
What is the dividend yield of Glenmark Life Sciences Ltd (GLS)?
What is the net margin of Glenmark Life Sciences Ltd (GLS)?
What is the return on equity of Glenmark Life Sciences Ltd (GLS)?
What is the EBIT return on assets of Glenmark Life Sciences Ltd (GLS)?
What is the operating margin of Glenmark Life Sciences Ltd (GLS)?
How fast is revenue growing at Glenmark Life Sciences Ltd (GLS)?
How fast are earnings growing at Glenmark Life Sciences Ltd (GLS)?
Watch Glenmark Life Sciences Ltd in the live analysis
One click puts Glenmark Life Sciences Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.